New radioactive antibody could make sickle cell transplants safer
NCT ID NCT07015684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a new drug called 131I-apamistamab, which combines an antibody with radioactive iodine, to prepare people with severe sickle cell disease for a bone marrow transplant. The goal is to find the smallest effective dose that allows the donor stem cells to take hold without the harsh side effects of standard conditioning. The study will enroll 24 patients aged 12 to 50 who have a matched sibling donor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 131I-apamistamab (a radioactive antibody)
- What this could lead to
- If successful, this could lead to a safer way to prepare sickle cell patients for a bone marrow transplant, potentially reducing side effects compared to standard conditioning.
- What could go wrong
- This is a very early (Phase 1) and small (24 people) study. The drug is experimental and not yet FDA-approved. There are risks from the radioactive component and the transplant itself, including graft failure or graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLING DISORDER DUE TO HEMOGLOBIN S are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Email: •••••@•••••